Single Nucleotide Polymorphism (SNP) Genotyping Market Report 2025

The single nucleotide polymorphism (SNP) genotyping market size has grown exponentially in recent years. It will grow from $10.3 billion in 2024 to $12.37 billion in 2025 at a compound annual growth rate (CAGR) of 20.1%. The growth in the historic period can be attributed to increasing research in genomics, rise in genetic disorders, growth in personalized medicine, expanding pharmaceutical industry, and rising demand for molecular diagnostics.

The single nucleotide polymorphism (SNP) genotyping market size is expected to see rapid growth in the next few years. It will grow to $24.95 billion in 2029 at a compound annual growth rate (CAGR) of 19.2%. The growth in the forecast period can be attributed to growing applications in disease research, a rise in demand for precision medicine, expanding biobanking initiatives, the surge in genetic testing, and rising adoption in agriculture for crop improvement. Major trends in the forecast period include increasing use of next-generation sequencing (NGS), rising demand for SNP genotyping in pharmacogenomics, the emergence of direct-to-consumer genetic testing, focus on automation, and high-throughput genotyping platforms.

The rising prevalence of chronic conditions is anticipated to drive the growth of the single nucleotide polymorphism (SNP) genotyping market in the coming years. Chronic conditions are health issues that persist for a year or longer, requiring ongoing medical care and often limiting daily activities. SNP genotyping plays a crucial role in identifying genetic predispositions and advancing personalized medicine in response to the growing prevalence of chronic diseases. For example, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that the death rate associated with chronic conditions increased from 459 deaths per 100,000 people in 2021 to 490 deaths per 100,000 people in 2022. Consequently, the increasing burden of chronic conditions is driving the growth of the single nucleotide polymorphism (SNP) genotyping systems market.

The increasing funding for genomic research is expected to drive the growth of the single nucleotide polymorphism (SNP) genotyping market in the future. Funding for genomic research refers to the financial resources allocated, granted, or invested to support activities in the field of genomics. Such funding is crucial for advancing SNP studies by facilitating various research initiatives, technology development, and collaborative projects. For instance, in September 2024, the National Institutes of Health (NIH), a US-based government agency, announced the allocation of $27 million to establish a new network of genomics-enabled learning health systems. Therefore, the rise in funding for genomic research is propelling the growth of the single nucleotide polymorphism (SNP) genotyping market.

A prominent trend in the single nucleotide polymorphism (SNP) genotyping market is the adoption of technological solutions. Major companies in this market are introducing advanced solutions to maintain their market position. For instance, in May 2022, Neogen Corporation and Gencove launched InfiniSEEK, the first complete genome and genotyping tool for cattle breeders. InfiniSEEK's validation demonstrates high concordance with deep whole-genome sequencing, providing clinical-grade accuracy in specific areas of interest. This technological advancement underscores the commitment of companies to bring innovative solutions to the single nucleotide polymorphism (SNP) genotyping market.

Companies in the single nucleotide polymorphism (SNP) genotyping market are also focusing on developing biomarkers for coronary heart disease detection, enhancing market profitability. Single nucleotide polymorphism (SNP) biomarkers associated with coronary heart disease (CHD) detection are genetic variations linked to an increased risk of CHD. For instance, Cardio Diagnostics launched PrecisionCHD in February 2023, an AI-driven blood test utilizing epigenetic and genetic biomarkers to detect CHD. This non-invasive test eliminates the need for traditional methods, providing objectivity through biomarkers rather than self-reported patient data.

In December 2023, Neogen Corporation, a US-based food safety company known for its diverse genomic technologies, particularly in single nucleotide polymorphism (SNP) genotyping, formed a partnership with TerraNova Equestrian Center. This collaboration aims to strengthen biosecurity measures at TerraNova Equestrian Center by implementing Neogen's advanced cleaning and disinfectant solutions. The focus is on protecting the health of horses and their owners while fostering a safe environment for equestrian competitions. TerraNova Equestrian Center is a US-based facility that offers premier services for riders and horses.

Major companies operating in the single nucleotide polymorphism (SNP) genotyping market include Thermo Fischer Scientific Inc., Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc., Eurofins Genomics LLC, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Sigma-Aldrich Corporation, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc., LGC Ltd., Sequenom Inc., Fluidigm Corporation, Agendia Inc., Nugen Technologies Inc., BioChain Institute Inc., Standard BioTools Inc., Oxford Gene Technology, Affymetrix Inc., PREMIER Biosoft International Inc., GenoLogics, Rubicon Genomics Inc., Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc.

North America was the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (snp) genotyping market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single nucleotide polymorphism (snp) genotyping market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Single nucleotide polymorphism (SNP) genotyping is a procedure that identifies and describes genetic variants at the level of specific DNA nucleotides. It focuses on pinpointing individual SNPs, which are single-base changes in DNA sequences. This process is crucial for gaining insights into genetic variations associated with diseases, traits, and population studies.

The primary products of single nucleotide polymorphism (SNP) genotyping include consumables, instruments, and services. Consumables refer to items that people and businesses regularly consume or use up, requiring replacement, such as food and home supplies. Various technologies are employed in SNP genotyping, including TaqMan SNP genotyping, Mass Array SNP genotyping, SNP gene chip arrays, and others. These technologies find applications in diverse fields such as animal genetics, plant improvement, diagnostic research, pharmaceuticals and pharmacogenomics, agricultural biotechnology, and more.

The single nucleotide polymorphism (SNP) genotyping market research report is one of a series of new reports that provides single nucleotide polymorphism (SNP) genotyping market statistics, including the single nucleotide polymorphism (SNP) genotyping industry's global market size, regional shares, competitors with a single nucleotide polymorphism (SNP) genotyping market share, detailed single nucleotide polymorphism (SNP) genotyping market segments, market trends and opportunities, and any further data you may need to thrive in the single nucleotide polymorphism (SNP) genotyping industry. This single nucleotide polymorphism (SNP) genotyping market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The single nucleotide polymorphism (SNP) genotyping market includes revenues earned by providing sample collection, DNA extraction, high-resolution melting analysis, and related next-generation sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. The single nucleotide polymorphism (SNP) genotyping market consists of sales of mass spectrometry-based SNP genotyping and allele-specific PCR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.